Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA’s 2024 Update
Health Populi
MAY 20, 2024
While patients starting new therapies slowed in 2020, they are back up and new chronic Rx’s 4% over the expected 2023 baseline. For defined daily doses, the league table leads with hypertension, followed by lipid regulators, mental health, anti-diabetics, GI and pain. Note that more than 92% of prescriptions in the U.S.
Let's personalize your content